Skip to Content

Cochlear Ltd COH

Morningstar Rating
A$320.72 +1.98 (0.62%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Elevated Growth Unlikely to Stay; Cochlear Shares Remain Expensive

Cochlear is the market leader in cochlear implants with consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-markets adults the next primary focus and emerging-markets children after that.

Price vs Fair Value

COH is trading at a 716% premium.
Price
A$318.74
Fair Value
A$592.00
Uncertainty
Medium
1-Star Price
A$813.00
5-Star Price
A$726.00
Economic Moat
Gqb
Capital Allocation
Hmqwhtth

Bulls Say, Bears Say

Bulls

There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on development of a hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.

Bears

Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COH is a good fit for your portfolio.

Trading Information

Previous Close Price
A$318.74
Day Range
A$317.56–320.99
52-Week Range
A$220.40–350.17
Bid/Ask
A$320.65 / A$320.74
Market Cap
A$20.99 Bil
Volume/Avg
4,639 / 122,304

Key Statistics

Price/Earnings (Normalized)
57.18
Price/Sales
9.77
Dividend Yield (Trailing)
1.18%
Dividend Yield (Forward)
1.25%
Total Yield
1.18%

Company Profile

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Growth
Total Number of Employees
4,500

Competitors

Valuation

Metric
COH
RMD
SOON
Price/Earnings (Normalized)
57.1825.7824.00
Price/Book Value
11.755.886.78
Price/Sales
9.776.024.63
Price/Cash Flow
48.7821.6521.44
Price/Earnings
COH
RMD
SOON

Financial Strength

Metric
COH
RMD
SOON
Quick Ratio
1.801.321.02
Current Ratio
2.573.041.45
Interest Coverage
50.9722.6323.78
Quick Ratio
COH
RMD
SOON

Profitability

Metric
COH
RMD
SOON
Return on Assets (Normalized)
14.09%15.75%10.91%
Return on Equity (Normalized)
20.32%24.94%26.88%
Return on Invested Capital (Normalized)
17.67%19.33%17.63%
Return on Assets
COH
RMD
SOON
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
HyddqptYkmlt$178.0 Bil
Stryker Corp
SYK
RplhbnpfhXfhmy$126.5 Bil
Boston Scientific Corp
BSX
JkfqqzzdyRfbdgj$111.9 Bil
Medtronic PLC
MDT
KyghsclSmqyhg$99.0 Bil
Edwards Lifesciences Corp
EW
McyyvnkqygVbgkzrp$54.9 Bil
DexCom Inc
DXCM
QbqqnmvpxXrlk$43.9 Bil
Koninklijke Philips NV ADR
PHG
YzlpbcvFqmpk$24.2 Bil
Zimmer Biomet Holdings Inc
ZBH
CphfbyjrsGjv$21.9 Bil
Steris PLC
STE
YygjsllJlwbm$21.5 Bil
Align Technology Inc
ALGN
BqpjlynjBlcxxh$18.3 Bil

Sponsor Center